ClinicalTrials.gg
RecruitingNCT07493876EPICHUpdated Apr 3, 2026

Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

An interventional study of ERAS Perioperative Management Protocol in Peritoneal Carcinomatosis, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2025, registered Mar 2026).
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Peritoneal Neoplasms with a site in Italy — 6 open to participants now, 8 under way, 3 of them phase 3. Peritoneal Neoplasms · Italy.

Planned enrollment
8th of 15
300 · median 300
Started
2025
with 2 others
No phase
2 of 18
1 open now
Registered
17th of 18
by date
Lead sponsor
2 of 18
Fondazione del Piemonte per l'Oncologia

Among the 18 studies in Peritoneal Neoplasms with a site in Italy, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 with no phase, and was the 17th registered.

Peritoneal Neoplasms

249 studies on the registry are indexed under Peritoneal Neoplasms; 54 are open to participants now.

Browse Peritoneal Neoplasms studies →

Open to participants now

6 of the 18 studies in Peritoneal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 48 Peritoneal Neoplasms studies recruiting now, 34 (71%) set no upper age limit and 8 (17%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Peritoneal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This prospective multicenter interventional pre-post study aims to evaluate the effect of implementing an Enhanced Recovery After Surgery (ERAS) protocol in patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Approximately 300 patients will be enrolled across 20 Italian centers. During an initial pre-intervention period, usual perioperative management will be described; during a subsequent intervention period, participating centers will apply a predefined ERAS protocol. The primary objective is to assess the effect of ERAS implementation on mean postoperative hospital length of stay.

Read the detailed description

Enhanced Recovery After Surgery (ERAS) is a multimodal perioperative care pathway designed to reduce surgical stress and accelerate postoperative recovery through coordinated evidence-based interventions involving surgery, anesthesia, nutrition, and rehabilitation. In patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC), postoperative morbidity and prolonged hospitalization remain clinically relevant issues. This study will evaluate the implementation of a selected ERAS protocol in this setting. The study is designed as a multicenter interventional pre-post study: during the first period (approximately 4 months; 100 patients), usual perioperative procedures will be documented; during the second period (approximately 8 months; 200 patients), centers will apply a predefined ERAS pathway. Monitored ERAS elements include prehabilitation and preoperative counseling, nutritional assessment and support, bowel preparation and antibiotic prophylaxis, perioperative fasting management, postoperative oral intake, fluid management, and intra-/postoperative analgesic management.

03

Conditions studied

  • Peritoneal Carcinomatosis

Browse trials for

Keywords

  • Cytoreductive Surgery
  • HIPEC
  • Enhanced Recovery After Surgery
  • ERAS
  • Peritoneal Surface Malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written signed before the procedure
  • Histological or cytological diagnosis of advanced solid tumor with documented peritoneal carcinomatosis originating from one of the following: peritoneal mesothelioma or other primary malignant peritoneal tumor, gynecologic tumor, gastric tumor, or intestinal tumor
  • Age >18 years
  • performance status ≤1
  • ≤3

Exclusion criteria

Exclusion Criteria:

  • Missing written
  • ≥4
  • Palliative surgery or other unplanned surgery
  • Severe renal insufficiency, severe hepatic insufficiency, severe heart failure, recent myocardial infarction, or severe arrhythmia
  • patients, patients receiving immunosuppressive therapy, or patients with immune system diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Usual Perioperative Management

    Participants enrolled during the first study period (approximately 4 months; expected n=100) will undergo usual perioperative management for cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) as routinely practiced at each participating center.

  • Other
    ERAS Perioperative Management Protocol

    Participants enrolled during the second study period (approximately 8 months; expected n=200) will undergo perioperative management according to a predefined Enhanced Recovery After Surgery (ERAS) protocol including preoperative counseling and prehabilitation, nutritional assessment and support, optimized fasting and carbohydrate loading, standardized antibiotic and antithrombotic prophylaxis, multimodal analgesia, goal-directed or restrictive fluid therapy, early oral intake, glycemic control, early mobilization, and discharge-readiness assessment.

    Other: ERAS Perioperative Management Protocol

Interventions

  • OtherERAS Perioperative Management Protocol

    A multimodal perioperative care pathway for patients undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC), implemented by a multidisciplinary Enhanced Recovery After Surgery (ERAS) team and including coordinated preoperative, intraoperative, and postoperative measures aimed at reducing surgical stress and improving recovery.

06

What researchers measure

Primary outcomes

  1. Postoperative Hospital Length of Stay

    Hospital length of stay measured in days from the date of surgery (Day 0) to the date of discharge from the index hospitalization. For the primary analysis, outliers with a hospital stay greater than the 95th percentile of the distribution will be excluded

    Time frame: From Day 0 (date of surgery) to hospital discharge, assessed up to 90 days after surgery

Secondary outcomes

  1. Adherence to Selected ERAS Protocol Items

    Adherence to the predefined ERAS perioperative items selected for monitoring, assessed across the preoperative, intraoperative, and postoperative phases of care

    Time frame: Perioperative period, from preoperative assessment before surgery through hospital discharge during the index hospitalization, assessed up to 30 days after surgery

  2. Incidence of Postoperative Complications

    Incidence of postoperative complications defined according to the Clavien-Dindo classification.

    Time frame: From the date of surgery to 30 days after surgery

  3. Postoperative Intensive Care Unit Length of Stay

    Length of postoperative intensive care unit (ICU) stay among participants admitted to the ICU after the index surgery, measured as the number of nights spent in intensive care

    Time frame: From postoperative ICU admission after the index surgery to ICU discharge, assessed up to 30 days after surgery

  4. Incidence of Reinterventions

    Incidence of surgical reinterventions after the index procedure.

    Time frame: From the date of surgery to 30 days after surgery

  5. Incidence of Hospital Readmissions

    Incidence of hospital readmissions after discharge following the index procedure.

    Time frame: From hospital discharge to 30 days after surgery.

  6. Incidence of Emergency Department Visits

    Incidence of emergency department visits after the index procedure.

    Time frame: From hospital discharge to 30 days after surgery.

  7. Time to Recovery of Bowel Function

    Time to recovery of bowel function, measured in days from the date of surgery to the first documented postoperative recovery of bowel function

    Time frame: From Day 0 (date of surgery) to first documented recovery of bowel function, assessed daily during the index hospitalization, up to 30 days after surgery

  8. All-Cause Mortality

    Incidence of death from any cause.

    Time frame: From the date of surgery to 30 days after surgery.

  9. Quality of Postoperative Recovery

    Mean quality of recovery score measured using the QoR-15 questionnaire.

    Time frame: Approximately 48 hours after surgery

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2026, 17 months after the start.

Of 34 interventional studies with no phase under Peritoneal Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 80. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 25, 2026
StartActual
Jan 23, 2025
Primary completionEst.
Jul 1, 2026
CompletionEst.
Dec 30, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493876
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Jan 23, 2025
Primary completion
Jul 1, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Manuela Robella, MD
Contact
manuela.robella@ircc.it
+390119933445

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion